Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0I7NG
|
|||
| Former ID |
DNCL002124
|
|||
| Drug Name |
LOR-2040
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60] | Phase 2 | [1] | |
| Breast cancer [ICD-11: 2C60-2C65] | Phase 2 | [1] | ||
| Metastatic colorectal cancer [ICD-11: 2B91; ICD-10: C19] | Phase 2 | [1] | ||
| Metastatic renal cancer [ICD-11: 2D50; ICD-10: C79.3] | Phase 2 | [1] | ||
| Prostate cancer [ICD-11: 2C82.0] | Phase 2 | [1] | ||
| Company |
Lorus Therapeutics
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00087165) GTI-2040, Docetaxel, and Prednisone in Treating Patients With Prostate Cancer. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.